Web of Science: 12 citas, Scopus: 12 citas, Google Scholar: citas,
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients : an expert taskforce review
García-Foncillas, J (Hospital Universitario Fundación Jiménez Díaz)
Alba, E (Hospital Universitario Regional Virgen de la Victoria, IBIMA, Málaga)
Aranda, E (Hospital Reina Sofía, Cordoba)
Díaz Rubio, E (Universidad Complutense de Madrid. Hospital Clínico San Carlos)
López López, R (Hospital Clínico Universitario (Santiago de Compostela))
Tabernero Caturla, Josep (Universitat Autònoma de Barcelona)
Vivancos, A (Vall d'Hebron Institut d'Oncologia)

Fecha: 2017
Resumen: The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93. 3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.
Derechos: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Lengua: Anglès.
Documento: article ; revisió ; publishedVersion
Materia: Colorectal cancer ; Mutation testing ; Liquid biopsy ; EGFR ; Tumor resistance
Publicado en: Annals of Oncology, Vol. 28 (september 2017) , p. 2943-2949, ISSN 1569-8041

PMID: 28945877
DOI: 10.1093/annonc/mdx501


7 p, 176.2 KB

El registro aparece en las colecciones:
Artículos > Artículos publicados

 Registro creado el 2018-12-31, última modificación el 2019-05-09



   Favorit i Compartir